News. Findings and events
Actual problem
Objective: assessment of the feasibility and safety of the use of ulipristal acetate on the basis of the clinical and morphological study.
Materials and methods: the study involved 78 women with leiomyoma, abundant menstruation and anemia. Group I – 43 patients who underwent ulipristal acetate therapy for three months and then laparoscopic myomectomy. Group II – 35 patients who were myomectomyed without presurgical preparation. A comparative analysis was made of the clinic-laboratory data, operational parameters, pathomorphological changes in the nodes and endometrium. According to the original clinical laboratory study groups I and II were almost homogeneous.
Results: in the case of ulipristal acetate therapy in all group I patients uterine bleeding ceased, the size of the myomatous nodules decreased by an average of 25 per cent according to the ultrasound and the MRI (p < 0.05), the haemoglobin and the ferritin levels reached normal values (p < 0.01). In group I there was a decline in the duration of the operation and blood loss compared to group II. Some leiomyoma reduction mechanisms have been identified. In endometrium of group I patients drug pathomorphosis after therapy was diagnosed. However, the immunohistochemical study made it possible to establish that these changes were benign and reversible.
Conclusions: presurgical treatment by ulipristal acetate of reproductive age patients with myomas, uterine bleeding and anaemia is appropriate, safe and pathogenetically justified. The possibility to use repeated courses of the drug, which may eventually postpone or cancel the need for surgical treatment is promising.
CLINICAL OBSERVATION
Contraception
The premenstrual syndrome (PMS) is a complex pathological symptom manifesting itselft through variety of neuropsychiatric, vegetative-vascular and metabolic-endocrine disorders that affect the quality of life of patients and reduces their working ability.
The treatment of PMS starts with the selection of diets, correction of the working and rest periods and the maximum reduction of psychoemotional stress. For the purpose of pharmaceutical effetc hormonal therapies, psychotropic drugs, nonsteroid antiinflammatory drugs, diuretics, plant and homeopathic drugs, vitamins are used. The most pathogenetically reasonable is hormonal therapy.
The use of combined oral contraceptives enriched by folates as a way of PMS therapy has an additional effective impact on the nervous system, contributes to the stabilization of the central neuroregulatory mechanisms and reduces the expression of emotional and affective symptoms and cognitive disorders.
ЭНДОМЕТРИОЗ
Pregnancy and childbirth
The frequency of iron-deficiency conditions (IDC) in pregnant women in the world ranges from 25 to 50% at the average. In developing countries, their prevalence ranges from 35 to 75%, and in developed ones amounts to 18-20%. According to the Ministry of Health of Russia, the average frequency of IDC in pregnant women in Russia ranges from 39 to 44%, and in postpartum women – from 24% to 27% [1–3].
Iron deficiency (ID) adversely affects pregnancy, childbirth, postpartum period, fetus and newborn conditions, contributing to the increase in the frequency of threatened abortion, placental insufficiency, delayed growth and fetal hypoxia, premature birth, uterine inertia, frequency and volume of pathological blood loss in childbirth and the early postpartum period, infectious complications and hypogalactia in postpartum women. Iron supplementation to prevent reduces the risk of anemia in motherto-time delivery by 70% and iron-deficiency States by 57%.
In the modern market of pharmaceutical industry the drug Sorbifer Durules has been well established (EGIS, Hungary). The use of this drug in a large sample of pregnant and postpartum women in recent years has proved its efficacy in the treatment of ID in this patient cohort.
The aim of the study was to compare the efficacy of tocolytic agents - hexoprenaline and atosiban taking into account the gestational age.
Patients and methods. The study included 147 pregnant women with threatening preterm labour between 28 to 33 weeks of gestation. Seventy-three pregnant received tocolysis by hexoprenaline (36 of them before 28 weeks of gestation and 37 – 32 weeks and more) and 74 – atosiban (39 of them before 28 weeks of gestation and 35–32 weeks and more). There were no differences in the clinical condition of pregnant women and features of preterm labour among groups before start of the tocolysis.
The degree of effectiveness is determined by the duration of the pregnancy prolongation (48 hours, 7 days, more than 14 days).
Results. Depending on the gestational age women that received hexoprenaline tocolysis prolonged pregnancy for 48 hours in 80,6% and 81,1%, whereas in the treatment with atosiban in 94,9% and 100%. Full-term gestation births occurred in 24,3% after hexoprenaline tocolysis at 32 weeks and more and in 51,4% with – atosiban (p < 0,05%). On average, atosiban tocolysis allowed to prolong pregnancy by 6–10 days longer than hexoprenaline (p < 0,05).
Conclusion: The results of study have shown that atosiban was more effective tocolytic than hexoprenaline in the treatment of threatening preterm labor in both 28-32 and 32 or more weeks of gestation. The efficacy of atosiban slightly increased with gestational age from 28 to 33 weeks.
Preterm birth is one of the most important problems of modern obstetrics. The etiology of preterm birth is multifactorial, including the maternal and fetal complications, on the background of functionally vulnerable variants of many genes, therefore preterm birth is considered as the big obstetric syndrome. One of the anatomical components of the syndrome is the uterine cervix. Frequently, in singleton pregnancy, single-most reliable prognostic marker is the untimely maturation of the cervix due to increased uterine contractile activity.
The selection of correction method for the short cervix relies on the clinical conditions, history, gestational age, number of fetuses, cervicometry data, gynecological examination data, threatening preterm birth or pregnancy loss, and the experience of the physician. Insertion of obstetric pessary is a promising, safe, simple method for treatment and prophylaxis of cervical insufficiency and threatened termination of pregnancy in II and III trimesters. The strategy of broad use of pessaries in the group of high-risk pregnant women allows to reduce the frequency of preterm birth and improve perinatal outcomes.
DIFFICULT DIAGNOSIS
INFECTIONS
Reproductive health and ART
Over the past few decades the incidence of infertility and sub-fertility has increased significantly, particularly in developed countries. External environmental factors, such as air and soil pollution, contact with different chemicals, are consdiered as the cause of both female and male fertility decline. Various lifestyle factors, such as nutrition, chronic diseases, stress, allergies, smoking and alcohol consumption, are also seen as potential causes of fertility decline.
The toxic effects of various harmful substances on a reproductive human system can lead to a disruption of the synthesis of steroid hormones, as well as to the direct damage to the tissue of reproductive organs. It is known that the main pathological mechanism for the negative effects of toxic substances on reproduction is the development of oxidized stress, an important component of various serious human diseases.
Antioxidants are a group of medications that neutralize the free radicals. Antioxidants include various vitamins, minerals, as well as polyunsaturated fatty acids. Various antioxidants (in the form of biologically active additives) and multivitamins are often indicated as preconception training for women and men who are planning a natural pregnancy and are experiencing a fertility problem or patients in the preparation for the program of auxiliary reproductive technologies (ART). The purpose of the drugs is to increase fertility and increase the effectiveness of the ART program, but the efficacy of such therapy has not been definitively defined.
This literature review provides the up-to-date literature data on the effects of vitamin A, C, E, omega-3-polyunsaturated fatty acids, melatonin and the Q10 coenzyme on various aspects of the human reproduction function.
PRE- AND POSTMENOPAUSE
DISSERTANT
Relevance: According to the literature, Vulvovaginal candidiasis (VVC) is diagnosed in 75% of women during life, and in 5-8% of women its recurrent course is developed (four or more episodes of exacerbation during 12 months). Recurrent vulvovaginal candidiasis (RVVC) is often observed in the presence of development risk factors, but often the recurrent course of the disease is developing among women without obvious risk factors. The literature shows that the development of a recurrent fungal infection is often caused by a violation of the local immune response, which is associated with the polymorphism of the immune system genes.
Objective of the study: To develop criteria for forecasting the recurrent current volvovaginal candidiasis to improve the effectiveness of therapy.
Study results: As a result of our study, it has been found that C. albicans remains the leading fungal species in the acute and recurrent VVC, but women with the recurrent course of VVC the prevalance of non-C. Albicans fungi is reliably higher than the patients with acute VVC (P = 0.037). Also, the sensitivity data obtained shows that most of the studied yeast fungi (97.5%) are sensitive to fluconazole. However, only in 10.5% of the non-C.Albicans strains resistance was detected. The determination of genetic predisposition to develop the recurrent current VVC, using the prediction model derived from our study, revealed that 77.8% of women with a genetic predisposition are developing a relapse of VVC. In view of these results and based on international recommendations (CDC, WHO, 2011) that it is appropriate to indicate the anti-recurring antifungal treatment to RVVC, it can be concluded that for patients with genetic predisposition to the development of recurrent VVC it is advisable to indicate the anti-recurrent antifungal therapy.
ISSN 2658-5790 (Online)